TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
Tumor-infiltrating regulatory T cells (Tregs) function to suppress T effectors, and its presence was reported to correlate with tumor progression and a worsening prognosis in many cancers.
TST010 displayed potent and selective Treg depleting activity and can liberate T effectors in tumor microenvironment to induce immune mediated killing of cancer cells in preclinical tumor models.
